James Thrasher, MD
Endocrinology, Diabetes & Metabolism · Little Rock, ARNPI 1841250875
Payments from drug & device makers
Across 2,148 payments — averaging $1882.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$2.7M
- Eli Lilly$687K
- Novo Nordisk AS$361K
- Sanofi US Services Inc.$101K
- AstraZeneca$47K
- Boehringer Ingelheim$23K
- plus $79K from 37 others
Across 3 payments — averaging $4486.81 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$13K
What the payments were for
- Consulting fees$33,29010%
- Speaking & faculty fees$265,20076%
- Travel & lodging$30,7289%
- Food & beverage$20,1666%
- Education$820%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MINIMED 780G$88,319
- Minimed 630G$71,063
- Minimed 670G System$32,420
- MINIMED 770G$23,036
- INVOKANA$14,534
- Kerendia$14,017
- SOLIQUA 100/33$13,504
- TOUJEO$8,268
- FARXIGA$6,575
- Eversense$6,015
- JARDIANCE$4,181
- Minimed 770G System$3,510
- RYBELSUS$2,790
- Ozempic$2,398
- InPen$1,970
- SIMPLERA SENSOR$996
- Guardian Sensor 3$620
- INPEN SMART INSULIN DELIVERY SYSTEM$233
- Wegovy$101
How this compares
$4,043,119 in reported general payments places this provider in the 95th percentile of 43 endocrinology, diabetes & metabolism providers in Arkansas.
See all endocrinology, diabetes & metabolism providers in Arkansas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 1,213 | $1,241,674 |
| MounjaroTirzepatide | 594 | $718,234 |
| JardianceEmpagliflozin | 721 | $532,490 |
| TrulicityDulaglutide | 154 | $169,416 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 146 | $145,547 |
| IsturisaOsilodrostat Phosphate | 13 | $132,111 |
| FarxigaDapagliflozin Propanediol | 156 | $128,349 |
| Humalog Kwikpen U-200Insulin Lispro | 53 | $107,005 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 60 | $92,286 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 177 | $86,297 |
| Tresiba Flextouch U-100Insulin Degludec | 149 | $83,262 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 107 | $83,187 |
| FiaspInsulin Aspart (Niacinamide) | 58 | $70,540 |
| NovologInsulin Aspart | 240 | $70,219 |
| JanuviaSitagliptin Phosphate | 83 | $69,370 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Fiasp, Novolog, Rybelsus | $4,150 | $1,426,6671,536 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro, Lyumjev | $4,036 | $970,6391,122 claims |
| Boehringer IngelheimJardiance, Tradjenta | $23,328 | $546,862748 claims |
| Recordati_rare_diseases_inc.Isturisa | $275 | $132,11113 claims |
| AstraZenecaFarxiga | $46,677 | $128,349156 claims |
| MerckJanuvia, Janumet Xr | $2,859 | $77,551100 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $22,929 | $27,58978 claims |
| BayerKerendia | $14,220 | $23,18536 claims |
| AbbVieSynthroid | $343 | $14,739229 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 43 endocrinology, diabetes & metabolism providers in Arkansas.
Other endocrinology, diabetes & metabolism in Little Rock
- Richard GriffithsLittle Rock$925K
- Madhu BudhrajaLittle Rock$461K
- Irina LendelLittle Rock$87K
- Donald BodennerLittle Rock$51K
- Richard RappLittle Rock$47K
- Shunzhong BaoLittle Rock$40K
- Teresa NimmoLittle Rock$29K
- Joseph HenskeLittle Rock$23K
- Nidhi JainLittle Rock$9K
- Archana JarathiLittle Rock$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.